Sodium Hyaluronate, Chondroitin Sodium Sulfate

Hyalur CS is intended for intraarticular injection.
The solution should not be injected outside the joint cavity, as well as in patients with infections or skin diseases in the area of ​​the injection.
Intra-articular injection should be administered by specialists who have been trained in the technique of intra-articular injection and should be made under aseptic conditions in medical institutions.
Perhaps the use of local anesthetics before intraarticular injection, for example, subcutaneous injection of lidocaine.
It is necessary to properly disinfect the injection site (use a solution of 70% alcohol or other disinfectants). Disinfectants containing quaternary ammonium salts (for example, benzalkonium chloride) should not be used, since precipitation is possible.
Before the introduction of Hyaluroma CS, fluid should be removed from the joint cavity.
It is recommended that arthrocentesis be performed before the solution is injected.
After removing the protective cap from the syringe tip, attach to the syringe
sterile needle. Usually, a needle with a size of 0.8x40 mm (21G) is used for the knee joint, for other joints we recommend using a needle of the required size (from 17G to 22G) depending on the joint.
Hyalur CS is injected into the joint in volume, depending on the size of the joint. The joint cavity should not be overloaded.
Each pre-filled syringe is intended for single use. The contents of the syringe should be used immediately after opening. Unused completely solution is not subject to storage and should not be re-sterilized.
After the injection of Hyaluroma CS, the patient is advised to adhere to a gentle regimen and avoid excessive or prolonged stress on the joints (for example, running or playing tennis) for 48 hours.

Adverse reactions

You may experience mild pain and swelling at the injection site.
The above symptoms are transient and usually disappear after 72 hours.

Contraindications

- the established hypersensitivity to the components of this medical device;
- the presence of active inflammatory or infectious processes in the joint;
- the presence of signs of active skin disease or skin infection in the area of ​​the intended injection;
- use in patients with an established diagnosis of an autoimmune disease or undergoing immunotherapy;
- use during pregnancy or lactation;
- age up to 18 years.